Isatuximab achieves myeloma cell killing via multiple mechanisms, including antibody-directed cellular cytotoxicity, antibody-dependent cellular phagocytosis, complement-dependent cytotoxicity, direct apoptosis, direct activation of natural killer cells, and inhibition of CD38 ectoenzyme activity [11–14]. The gene discussed is CD38; the disease is plasma cell myeloma.